Literature DB >> 3130908

Fibrinolytic properties of a human endothelial hybrid cell line (Ea.hy 926).

J J Emeis1, C J Edgell.   

Abstract

The fibrinolytic characteristics of the endothelial hybrid cell line EA.hy 926, established by fusing a human umbilical vein endothelial cell with a human carcinoma cell line, were studied. The hybrid cell line produced large amounts of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1, and a small amount of urokinase. All plasminogen activator present in conditioned medium was complexed with inhibitor because the cells secreted plasminogen activator inhibitor in excess over plasminogen activator and no activator activity was detectable in conditioned media by direct activity assays. t-PA activator activity was, however, demonstrable in conditioned media after treatment with sodium dodecyl sulfate, in agreement with t-PA antigen determinations. Increased plasminogen activator inhibitor activity could be induced by incubating the cells in the presence of endotoxin or microtubule inhibitors, whereas increased t-PA activity could be induced by microtubule inhibitors. Interleukin-1 had no effect. The fibrinolytic characteristics of the hybrid cell line were stable for at least 30 passages. The perpetual human hybrid cell line EA.hy 926 therefore may be a useful tool for the study of fibrinolysis in cultured endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130908

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains.

Authors:  J Partanen; E Armstrong; T P Mäkelä; J Korhonen; M Sandberg; R Renkonen; S Knuutila; K Huebner; K Alitalo
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

2.  Growth characteristics of a permanent human endothelial cell line.

Authors:  H I Schaefer; F M van 't Hooft; A van der Laarse
Journal:  In Vitro Cell Dev Biol       Date:  1992 Jul-Aug

3.  Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926.

Authors:  C J Edgell; J E Haizlip; C R Bagnell; J P Packenham; P Harrison; B Wilbourn; V J Madden
Journal:  In Vitro Cell Dev Biol       Date:  1990-12

4.  Responses of HUVEC and EAhy926 to heparin and fibroblast growth factors.

Authors:  S Thomas; C J Robinson; E Gray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Jul-Aug       Impact factor: 2.416

5.  On measuring the third dimension of cultured endothelial cells in shear flow.

Authors:  S Q Liu; M Yen; Y C Fung
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

6.  Modified Ham test for atypical hemolytic uremic syndrome.

Authors:  Eleni Gavriilaki; Xuan Yuan; Zhaohui Ye; Alexander J Ambinder; Satish P Shanbhag; Michael B Streiff; Thomas S Kickler; Alison R Moliterno; C John Sperati; Robert A Brodsky
Journal:  Blood       Date:  2015-04-10       Impact factor: 22.113

7.  Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Authors:  Tashanna Myers; Shylet Chengedza; Stan Lightfoot; Yanfang Pan; Daynelle Dedmond; Lauren Cole; Yuhong Tang; Doris M Benbrook
Journal:  Invest New Drugs       Date:  2008-09-18       Impact factor: 3.850

8.  Net transport of cholesterol from cells of the human EA.hy 926 endothelial cell line to high density lipoproteins.

Authors:  E P Kilsdonk; A N Dorsman; A van Tol
Journal:  Experientia       Date:  1993-07-05

9.  Serum immunoglobulin G reactive with endothelial cells in inflammatory bowel disease.

Authors:  A M Sawyerr; B E Pottinger; C O Savage; N J Bradley; M Hudson; A J Wakefield; J D Pearson; R E Pounder
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

10.  Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity.

Authors:  Christian H Schweppe; Martina Bielaszewska; Gottfried Pohlentz; Alexander W Friedrich; Heino Büntemeyer; M Alexander Schmidt; Kwang S Kim; Jasna Peter-Katalinić; Helge Karch; Johannes Müthing
Journal:  Glycoconj J       Date:  2008-01-05       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.